Click here to read the articles and download the PDF

Pharmaceutical Commerce - August 2022

While companies in this space are grappling with issues ranging from inflation and supply chain disruption to workforce scarcity and DSCSA implementation, there’s still plenty of room for smaller players to stake out part of the terrain to call their own

Pharma Distribution: Carving New Ground

Exploring the competitive and unique offerings in three of the US’s lower-cost economic development regions—and how success in these areas has been boosted by COVID

Regions On Rise: Life Sciences Across US

A look into one of the East Coast’s major life science hubs

Tapping Industry’s Reach in Maryland

Articles

With the use of mRNA vaccines on the rise, so is the need for dedicated freezing and storing solutions

Cold Chain: a Hot Topic for mRNA Vaccines

Acquisition of healthcare logistics company to play a role in delivery of pharma and biologic treatments

UPS Inks Deal for Bomi Group

Nitin Raizada is VP, Enterprise Commercial; Arindam De, is Director, Enterprise Commercial; and Durgagauri Sabnis, PhD, is Manager, Product Marketing, all at 

Five strategies to help pharma companies improve their return on investment from adherence-promoting initiatives and drive positive health outcomes for patients

5 Ways to Tackle Patient Non-Adherence

Podcasts

A look into the effectiveness of data processing pipelines 

Intertwining Technology and Data Solutions

Multi-year deal aims to put patients at the center of their clinical data

Seqster, Boehringer Ingelheim, Partner up on Patient Engagement

Association’s director general recommends air cargo developments be closely monitored in second half of year

June Air Freight Stats Support Resiliency, IATA Says

New facility will provide lyophilization services

Oregon Freeze Dry Opens $7.5 Million Biopharma Facility

Division will operate under SCHOTT Pharma AG & Co. KGaA

SCHOTT Creates Stand-alone Company for Pharma Business

With the business model changing and the patent cliff looming, Ashfield Engage's Chris Savage talks about what these upheavals mean for pharma companies, their sales reps, and their patients


Shaping Strategies for a New Era of Engagement and Commercialization

, which provides strategy consultancy to pharma and healthcare providers that are embracing transformation. Based in the UK, Richard is a specialist in commercialization strategy; commercial evaluations and due diligence; strategic analytics and forecasting; brand performance management; lifecycle management strategy; pre-launch planning; competitive intelligence and market research.

Richard’s therapy area expertise includes cardiovascular and metabolic disease, renal disease, oncology and dermatology. Richard holds a PhD in cardiovascular disease from Cambridge University, an MBA from The Open University. He is a Chartered Biologist and a Member of the Royal Society of Biology.

 and has extensive expertise in providing advice to biopharma leaders from global to local country affiliate. Having worked in blue-chip pharma at Merck Sharp & Dohme (MSD) for many years in commercial roles at senior management and board-level positions, he is well acquainted with how a large multinational operates and some of the day-to-day complexities. During this time at MSD, he gained invaluable experience and reputation in several therapy areas including cardio & metabolic disease, neurology, pain, urology, oncology and anti-infectives. Building brands and commercializing assets is his forte.

How cross-functional commercialization teams can hone their role within clinical management pathways, communicate value to all stakeholders, achieve excellence in evidence generation, and maximize the opportunities of digital technologies

Featured Content

Pharmaceutical Commerce - August 2022

Pharma Distribution: Carving New Ground

Regions On Rise: Life Sciences Across US

Tapping Industry’s Reach in Maryland